Optimizing Treatment Strategies for Metastatic NSCLC: Achieving the Best Patient Outcomes
The video series, Optimizing Treatment Strategies for Metastatic NSCLC: Achieving the Best Patient Outcomes, provides expert insights on patient selection, treatment sequencing, and managing adverse events to improve care for EGFR+ and ALK+ metastatic NSCLC patients.
EP. 1: Robert’s Journey With EGFR+ Metastatic NSCLC
The video segment profiles a 58-year-old retired construction manager with Stage IV EGFR+ NSCLC, discussing his transition from osimertinib to amivantamab plus chemotherapy, managing side effects, and maintaining hope throughout his treatment journey.
EP. 2: The Impact of Molecular Testing on Treatment Choices for NSCLC
A discussion with Dr. Garon highlights patient selection for EGFR inhibitor therapy in EGFR+ NSCLC, emphasizing the critical role of biomarker testing, testing approaches, and overcoming barriers in community settings.
EP. 3: Overview of FLAURA and MARIPOSA-2 Clinical Trials
Dr. Kim reviews key clinical evidence from the FLAURA trial for osimertinib as a first-line therapy in EGFR+ metastatic NSCLC and discusses the MARIPOSA 2 trial supporting amivantamab with chemotherapy as the preferred second-line option.
EP. 4: Clinical Experience of Amivantamab in EGFR+ NSCLC Patients
Dr. Kim shares his clinical experience with amivantamab in real-world practice for EGFR+ NSCLC, discussing both the benefits and challenges of incorporating it into treatment protocols.
